Draft guidance

CBER has published a draft guidance for comments from industry concerning gene therapy clinical trials and observing participants for delayed adverse events. It gives recommendations to sponsors of gene therapy studies regarding the design of studies to include the collection of data on delayed adverse events in parti-cipants who have been exposed to gene therapy products.